Regenxbio (RGNX) – Investment Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Regenxbio (NASDAQ: RGNX):

  • 8/1/2019 – Regenxbio was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating.
  • 8/1/2019 – Regenxbio was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/25/2019 – Regenxbio was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland. “
  • 7/19/2019 – Regenxbio was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 7/17/2019 – Regenxbio was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland. “
  • 7/15/2019 – Regenxbio was given a new $84.00 price target on by analysts at Morgan Stanley. They now have a “buy” rating on the stock.
  • 7/11/2019 – Regenxbio was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 6/18/2019 – Regenxbio was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 6/18/2019 – Regenxbio had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $150.00 price target on the stock, up previously from $145.00. They wrote, “We note Sarepta Therapeutics (unrated) may be relevant for that theme. The IP discussion began by REGENXBIO discussing Zolgensma and the agreement with Avexis, a Novartis (unrated) company, where REGENXBIO will receive tiered royalties of 6%, 8%, and 10% on Zolgensma sales of $600 mm, respectively, as well as a milestone payment of $80 mm once Zolgensma reaches $1 bn in aggregate sales.””
  • 6/13/2019 – Regenxbio is now covered by analysts at Raymond James. They set an “outperform” rating on the stock.

Regenxbio stock traded down $0.34 during mid-day trading on Wednesday, reaching $40.76. The stock had a trading volume of 6,191 shares, compared to its average volume of 522,144. The company has a debt-to-equity ratio of 0.01, a current ratio of 14.21 and a quick ratio of 14.21. Regenxbio Inc has a fifty-two week low of $35.70 and a fifty-two week high of $83.45. The company has a 50-day simple moving average of $48.17. The stock has a market cap of $1.51 billion, a price-to-earnings ratio of 17.13 and a beta of 0.71.

Regenxbio (NASDAQ:RGNX) last announced its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.89) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.85) by ($0.04). Regenxbio had a negative net margin of 41.99% and a negative return on equity of 9.90%. The firm had revenue of $0.88 million during the quarter. As a group, equities research analysts expect that Regenxbio Inc will post -2.4 earnings per share for the current year.

In other Regenxbio news, insider Kenneth T. Mills sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 19th. The stock was sold at an average price of $52.54, for a total value of $788,100.00. Following the completion of the sale, the insider now owns 261,000 shares of the company’s stock, valued at $13,712,940. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Patrick J. Christmas sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 18th. The shares were sold at an average price of $52.99, for a total value of $264,950.00. Following the completion of the sale, the senior vice president now directly owns 8,006 shares of the company’s stock, valued at approximately $424,237.94. The disclosure for this sale can be found here. Insiders sold 73,000 shares of company stock valued at $3,590,400 in the last three months. Insiders own 13.80% of the company’s stock.

Several hedge funds have recently bought and sold shares of RGNX. Mckinley Capital Management LLC Delaware lifted its holdings in shares of Regenxbio by 51.8% in the first quarter. Mckinley Capital Management LLC Delaware now owns 888 shares of the biotechnology company’s stock valued at $51,000 after purchasing an additional 303 shares in the last quarter. Financial Gravity Wealth Inc. bought a new stake in Regenxbio during the first quarter worth $55,000. Berman Capital Advisors LLC lifted its holdings in Regenxbio by 41.6% during the second quarter. Berman Capital Advisors LLC now owns 1,133 shares of the biotechnology company’s stock worth $58,000 after acquiring an additional 333 shares during the period. NEXT Financial Group Inc bought a new stake in Regenxbio during the second quarter worth $69,000. Finally, SG3 Management LLC bought a new stake in Regenxbio during the first quarter worth $115,000. Institutional investors own 80.97% of the company’s stock.

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

See Also: Different Types of Derivatives

Receive News & Ratings for Regenxbio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio Inc and related companies with MarketBeat.com's FREE daily email newsletter.